Jason Bock, Ph.D.
Professional Summary
Jason Bock, Ph.D., serves as the CEO of the Cell Therapy Manufacturing Center (CTMC), a joint venture between Resilience and MD Anderson Cancer Center. Dr. Bock has extensive experience in biologics development and commercialization, with over 20 years in the sector. He is renowned for his role in spearheading innovative cell therapy initiatives aimed at treating and curing cancer.
Current Role and Responsibilities
Dr. Bock was appointed CEO of CTMC in May 2022. Under his leadership, CTMC focuses on combining academic research with industrial drug development to expedite the creation and deployment of cell therapies. The center operates from a 60,000-square-foot facility in the Texas Medical Center featuring 14 cleanrooms, process and analytical laboratories, and office space.
- Achievements at CTMC:
- Successfully navigated three novel cell therapies through Investigational New Drug (IND) clearance.
- On track to submit six novel cell therapies for IND clearance within the next 18 months.
CTMC’s mission includes leveraging cutting-edge manufacturing techniques and collaborative partnerships to accelerate the availability of life-saving treatments.
Career Background
Prior to joining CTMC, Dr. Bock held pivotal roles in the pharmaceutical industry:
- Teva Pharmaceuticals:
- Served as Site Head and Vice President of Global CMC Biologics in the Specialty R&D Division.
- Led the Biologics team, growing it to over 600 employees.
- Successfully advanced 15 novel drugs from preclinical development into clinical trials.
- Oversaw the transition of three biologics from clinical trials to global commercialization.
- Previous Roles:
- Integral in the acquisition and integration of CoGenesys by Teva Pharmaceuticals.
- Initial career began at Human Genome Sciences (HGS), where he co-founded CoGenesys.
Education
- Bachelor of Science (BS) in Biology from the Massachusetts Institute of Technology (MIT) (1990 - 1994).
- Ph.D. in Molecular and Cellular Physiology from Stanford University.
Notable Appearances and Publications
- Speaker Engagements and Panels:
- Featured in various industry podcasts and panels discussing topics such as the industrialization of precision medicine and the challenges in cell therapy manufacturing.
- Recent engagements include a keynote address titled "Accelerating the Cell Therapy Transformation" and a panel discussion on the pros and cons of centralized vs. point-of-care CAR-T manufacturing.
- Public Recognition:
- Recognized in The Medicine Maker Power List for 2024 under the Advanced Medicines category.
- Regularly publishes thought leadership articles and participates in high-profile biotech forums and conferences.
Upcoming Engagements
- SITC Annual Meeting: Scheduled to participate in a half-day pre-conference workshop on Tumor Infiltrating Lymphocytes (TIL) Therapy followed by a roundtable discussion in November 2024.
Strategic Vision
Under Dr. Bock’s leadership, CTMC aims to:
- Enhance the efficacy and accessibility of cell therapies.
- Integrate advanced data platforms and innovative manufacturing techniques.
- Foster collaborations with biotechnological partners to continuously improve cell therapy processes and outcomes.
Contact Information
- LinkedIn Profile: [Jason Bock's LinkedIn](https://www.linkedin.com/in/jason-b-bock)
Dr. Jason Bock's strategic vision and extensive experience in biologics development position him as a leading figure in the advancement of cell therapy manufacturing. His efforts at CTMC are pivotal in driving the joint venture's mission to engineer effective treatments that bring hope to patients suffering from complex diseases such as cancer.
